A Medicare experiment could change who gets Ozempic

The government’s five‑year experiment could be the first step toward broad public coverage of GLP‑1 drugs.

If a new experiment pans out, Medicaid and Medicare could begin covering the costly weight-loss drugs that price out many Americans who might want to try them.